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Abstract
The purpose of this QI project was to improve provider adherence to the Institute for Clinical
Systems Improvement (ICSI) Guidelines for Adult Depression in Primary Care to enhance the
screening, diagnosis, treatment, and management of adult major depressive disorder (MDD).
MDD is a widespread, disabling, and treatable psychiatric disorder that is primarily treated and
managed by primary care providers (PCPs). Untreated depression is prone to become chronic
and can lead to pain, suffering, disability, increased morbidity and mortality, and premature
death, with serious repercussions for the individual and society. Universal and routine screening
in primary care for depression in adults, in combination with adequate systems of support, is
recommended by ICSI guidelines and has been found to be a cornerstone in the management of
MDD. Despite this, depression remains underrecognized, underdiagnosed, and undertreated in
primary care. The project objectives aimed at aligning the clinic with ICSI’s guidelines to
increase screening for depression, routine assessment for the severity of symptoms, referrals to
behavioral health specialists (BHS), and minimize suicide risk. An MDD protocol was developed
and all adult patients were universally and routinely screened for depression using PHQ-2 and/or
PHQ-9 over an 8-week period. Project interventions were successful at initiating change toward
improving provider adherence to ICSI guidelines. Screening rates for depression, routine
assessment rate for the severity of symptoms, provider adherence rate to the suicide protocol, and
the referral rate to a BHS increased from pre-intervention to post-intervention.
Keywords: Major depressive disorder, MDD, primary care, adult depression, depression
screening, PHQ-9
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Impact of Depression
Major depression is a common and treatable psychiatric disorder that affects over 300
million individuals globally and roughly 9% of the U.S. population (Maurer, Raymond, & Davis,
2018; World Health Organization [WHO], 2018). This disabling disorder is associated with
astronomical medical costs and is linked to diminished role functioning and quality of life and
increased morbidity and mortality; it is also linked with major co-morbidities such as arthritis,
cardiovascular disease, asthma, cancer, diabetes, hypertension, and chronic respiratory and pain
conditions (Institute for Clinical Systems Improvement [ICSI], 2016; Kessler & Bromet, 2013).
If left untreated, major depression can lead to extensive pain, suffering, disability, increased
morbidity and mortality, and even death (ICSI, 2016; Maurer et al., 2018).
Approximately 13 to 16% of adults in the United States will endure symptoms of
depression in their lifetime, and nearly 4 to 8% of adults suffer from major depression in a given
year (American Psychiatric Association [APA], 2017). A majority of Americans with depression
seek care and treatment in primary care setting, with PCPs prescribing 79% of antidepressant
medications and providing care for nearly 60% of patients with depression (Barkil-Oteo, 2013;
ICSI, 2016; Maurer et al., 2018). Yet PCPs fail to recognize major depression in up to one half of
their patients with depression (APA, 2017; ICSI, 2016; Maurer et al., 2018). Consequently, less
than one half of adult patients experiencing major depression actually receive treatment, with
only 20 to 40% of those being treated showing significant improvement over a 12-month period
(ICSI, 2016). Routine screening for depression in adults 18 years of age and over is
recommended by the ICSI guidelines for adult depression in primary care and the U.S.
Preventive Services Task Force (USPSTF) in combination with adequate systems of care in
place, and is cornerstone for the recognition, diagnosis, treatment, and management of
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depression (ICSI, 2016; Maurer et al., 2018). Despite the USPSTF’s recommendation, screening
rates for depression remain low in primary care, with less than 5% of adults being screened
(APA, 2017a). With depression being underdetected, underdiagnosed, and undertreated in
primary care, there is a crucial need for PCPs to be adequately skilled in the recognition,
diagnosis, treatment, and management of major depression (ICSI, 201; Maurer et al., 2018).
PCPs are instrumental for the improvement of the recognition, diagnosis, and treatment of major
depressive disorder (MDD), and without adequate screening and adherence to evidence-based
guidelines for depression the patient, their loved ones, and society will continue to suffer from
the deleterious effects of this burdensome disorder (Cameron, Habert, Anand, & Furtado, 2014;
ICSI, 2016; Maurer et al., 2018).
Statement of the Problem
Major depression is a common, disabling, and treatable psychiatric disorder that affects
over 300 million people globally and 9% of Americans (WHO, 2018; Maurer et al., 2018).
According to WHO (2018), depression is a leading cause of disability and is projected to become
the second leading cause of disability globally by 2020 (Kessler & Bromet, 2013). This
psychiatric disorder is associated with astronomical societal costs and greater functional
impairment than many other chronic diseases, including arthritis and diabetes (Centers for
Disease Control and Prevention [CDC], 2018). Rates of depression differ based on age, sex,
income, and health behaviors (CDC, 2018).
Despite depression being a treatable disorder and the majority of patients with depression
receiving care from PCPs, depression is typically underrecognized, underdiagnosed, and
undertreated in the primary care setting (Cameron et al., 2014; Maurer, 2012;). In most cases,
even with recognition and treatment, outcomes are less than optimal, with greater than 75% of
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depressed patients in the United States experiencing recurrence (Maurer, 2012). Untreated
depression is likely to become a chronic disease and experiencing just one episode of depression
places an individual at a 50% greater risk for experiencing another episode, only further
increasing the chances of recurrence (APA, 2013). Untreated depression can lead to pain,
suffering, increased morbidity and mortality, and even death from suicide, with serious
repercussions for the individual, their family, and society (Maurer et al., 2018). Depression is
underrecognized, underdiagnosed, and undertreated in primary care, highlighting the need for
universal routine screening for adults per the USPSTF recommendations and adherence to
evidence-based guidelines by PCPs, such as the ICSI (2016) guidelines for adult depression in
primary care, to enhance the diagnosis, treatment, and management of MDD (APA, 2010; ICSI,
2016; Maurer et al., 2018).
Background and Significance
Depression is a widespread mental health disorder that is on the rise and affects nearly
300 million people of all ages globally (WHO, 2018). Major depression is one of the most
common mental disorders in the United States and, according to the 2016 National Survey on
Drug Use and Health study, approximately 16.2 million American adults suffer from depression,
which roughly equates to 6.7% of the adult population (National Institute of Mental Health
[NIMH], 2017). The 12-month prevalence of MDD in the United States is nearly 7%, with
females experiencing 1.5 to 3-fold higher rates (8.5%) compared to males (4.8%) (APA, 2013;
NIMH, 2017). Incidence of depression globally is 3% (Jesulola, Micalos, & Baguley, 2018).
Depression is one of the leading causes of injury and disability worldwide and is
associated with higher rates of chronic disease, significant health care needs and utilization,
impaired functioning, increased mortality from suicide, premature death, and overall higher
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morbidity and mortality (CDC, 2018; Kessler & Bromet, 2013; WHO, 2018). Individuals with
major depression have an overall increased risk of mortality 1.4 times greater than that of the
general population and are more prone to premature death than the general population as a result
of untreated mental or physical health issues (Funk, Drew, & Knapp, 2012). Mental health is
crucial to an individual’s wellbeing, to strong family and interpersonal relationships, and to live a
full and valuable life (Office of Disease Prevention and Health Promotion, 2018). Mental health
and physical health are indistinguishably connected and it is well established throughout the
literature that depression is significantly correlated with the risk, occurrence, management,
progression, and outcomes of severe chronic diseases and conditions such as diabetes, stroke,
hypertension, asthma, arthritis, cancer, cardiovascular disease, arthritis, and a multitude of
chronic pain conditions and mental health disorders that account for higher mortality rates and
premature death in comparison with the general population (Kessler & Bromet, 2013; Office of
Disease Prevention and Health Promotion, 2018). Individuals with depression often have
comorbid conditions, and undiagnosed or untreated depression can lead to worsened outcomes in
cardiovascular disease, cancer, and other conditions (ICSI, 2016).
The burden of depression has an impact on the depressed individuals, but can also
adversely affect their families, society, and the health care system as a whole (CDC, 2016). The
direct financial impact or economic burden is pretty straightforward and measures health care
expenditures, which were estimated to be $210.5 billion dollars in 2010 for depression, and
included workplace costs, direct costs, and suicide-related costs (Greenberg, Fournier, Sisitsky,
Pike, & Kessler, 2015). The indirect financial impact is all other costs related to depression,
which is not as straightforward as the direct financial impact. Depression is costly on the
individual level in many ways, as it tends to be associated with higher risk of morbidity and
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mortality, premature death particularly related to suicide, functional impairment, low education
level, marital disruption, reduced role functioning, elevated risk of comorbidities, low income,
low work performance, and unemployment, which only compound the financial burden
(Scrandis & Watt, 2013). The burden of depression nationally and globally is astronomical, as
higher costs are associated with increased health care needs (Maurer, 2012). Although there are
known efficacious treatments available for depression, fewer than half of the individuals affected
receive adequate treatment, which is linked to higher health care costs and poor health outcomes
(Maurer, 2012; WHO, 2018). Another issue contributing to the global burden and rising costs
associated with depression is the misdiagnosis or mismanagement of the disease (WHO, 2018).
Depression can be recurrent or persistent, and substantially impairs cognitive, social,
physical, and overall functioning (Jesulola et al., 2018). The underlying cause of depression is
complex with a number of factors being implicated in the pathogenesis (Jesulola et al., 2018).
Despite continued research efforts in the understanding of the pathogenesis of depression, the
precise mechanisms in which depression develops is unknown which is partly due to depression
being a complex and heterogenous disorder with numerous potential etiologies (Jesulola et al.,
2018). A number of factors alone and in combination, such as genetics, biogenic amine
deficiency, environmental, immunologic, endocrine, and neurogenesis, have been identified in
the literature as playing a role in the pathophysiology of depression (Jesulola et al., 2018).
Evidence supports the role of particular neurotransmitters such as the 5HT serotonin receptors,
Norepinephrine (NE), and Dopamine (DA) in the development and clinical manifestation of
depression and is aligned with the monoamine hypothesis that proposes that reduced availability
of these monoamine neurotransmitters results in decreased neurotransmission and neurocognitive
function, which may consequently lead to depression (Jesulola et al., 2018). Although evidence
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suggests that genetics plays a role in the development of depression, only a small number of
genetic polymorphisms have significant relationships with MDD, and include the APOE, GND3,
MTFHR 6771T, SLC6A3, SLC6A4, and the DRD4 genes (Jesulola et al., 2018). Hormonal and
endocrine dysfunction, Hypothalamus-Pituitary-Adrenal axis dysfunction, and a number of
immunological or inflammatory cytokines have also been correlated to the pathogenesis of
depression (Jesulola et al., 2018).
The Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5) classifies
mental health/psychiatric disorders, includes diagnostic criteria for depression, and per ICSI
guidelines, should be utilized by the PCP to establish the diagnosis of depression (APA, 2013;
ICSI, 2016). Classic symptoms of depression include a depressed mood, loss of interest in
activities, difficulties with concentration, feelings of guilt, sadness, or worthlessness, and suicidal
ideation (APA, 2013; ICSI, 2016; Kessler & Bromet, 2013). Per the DSM-5, depressive
disorders include MDD, persistent depressive disorder (dysthymia), premenstrual dysphoric
disorder, disruptive mood dysregulation disorder, substance/medication induced depressive
disorder, depressive disorder due to another medical condition, other specified depressive
disorder, and unspecified depressive disorders, with two of the most common forms consisting of
MDD and persistent depressive disorder (APA, 2013; NIMH, 2016). The common feature of all
of these depressive disorders is the presence of a sad, depressed, irritable mood accompanied by
cognitive and somatic disturbances that affect the individual’s functional capacity; the duration,
timing, and presumed etiology are what differs among the disorders (APA, 2013).
MDD represents the classic condition within the depressive disorders and requires five or
more of the following symptoms: depressed mood (most of the day), marked loss of
interest/pleasure in activities, significant and unintentional weight loss/gain or changes in
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appetite, insomnia/hypersomnia, psychomotor agitation/retardation, fatigue/loss of energy,
feelings of worthlessness/excessive or inappropriate guilt, decreased ability to think or
concentrate/indecisiveness, recurrent thoughts of death/suicidal ideation/suicide attempt. Per the
DSM-5 diagnostic criteria, these must be present nearly every day, with the exception of weight
change and suicidal ideation, and must be present during the same 2-week period and represent a
clear-cut change from previous functioning (APA, 2013). At least one of the symptoms must be
either depressed mood or loss of interest or pleasure in order for the diagnosis to be established
(APA, 2013; ICSI, 2016). MDD diagnostic criteria requires the episode to be of at least two
weeks’ duration, with symptoms that cause clinically significant distress or impairment in social,
occupational, or other areas of functioning that cannot be attributable to a substance or medical
condition (APA, 2013; ICSI, 2016). In addition, the episode must not be better explained by
schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other
schizophrenia spectrum/psychotic disorders (APA, 2013). Finally, the patient should never have
had a manic or hypomanic episode, although this exclusion does not apply if the mania or
hypomania was substance or medically induced (APA, 2013; ICSI 2016).
Current evidence-based treatment of MDD includes a pharmacologic approach alone or
in combination with non-pharmacological approaches such as cognitive behavioral therapy
(CBT) or psychotherapy, and/or Electroconvulsive Therapy (ECT), depending on the symptoms
and severity as recommended in the ICSI 2016 guidelines (APA, 2010; ICSI, 2016; Maurer,
2012). Selection of the initial treatment approach should consider clinical features such as the
severity of symptoms, the presence of co-occurring conditions, and other factors such as prior
treatment history or responses and patient preferences (Anderson, 2011; APA, 2010; ICSI,
2016). Pharmacologic evidence-based treatment with first-line antidepressants such as Selective
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Serotonin Reuptake Inhibitors, Serotonin Norepinephrine Reuptake Inhibitors, Norepinephrine
Dopamine Re-uptake Inhibitors, or mirtazapine are recommended for a period of at least six
months per the ICSI 2016 guidelines, with assessment of efficacy at four weeks to be determined
by a 50% reduction in symptoms and tolerance of side effects, which can be measured using the
Patient Health Questionnaire-9 (PHQ-9) (Anderson, 2011; APA, 2010; ICSI; 2016; Maurer,
2012). Re-evaluation of efficacy should be performed at six, eight and 12 weeks and if there is
not a 50% reduction in symptoms by eight weeks, the antidepressant should be substituted for
another first-line antidepressant (Anderson, 2011; APA, 2010; Maurer, 2012). Maintenance with
first-line antidepressant should continue at an optimal and tolerated dose for at least six months
(Anderson, 2011; APA, 2010; Maurer, 2012).
The overall treatment goals for depression aim to achieve remission of the depressive
episode (i.e., PSQ-9 score of less than 5), resolution of depressive symptoms, a return to the
patient’s baseline level of functioning, and a prevention of future relapse (APA, 2010; Anderson,
2011; Cameron et al., 2014; ICSI, 2016). The PHQ-9 assessment should be used routinely for
subsequent visits by PCPs as a management tool to monitor the severity and treatment outcomes
of depression (ICSI, 2016). This measurement-based approach to depression care, with
consideration of PHQ-9 results and side effect evaluation in combination with evidence-based
treatment algorithms, can help guide the PCP in the treatment of depression and toward
remission for the patient (ICSI, 2016; Siu et al., 2016). The PHQ-9 assessment is also a valid
tool to assess the risk for or presence of suicide ideation and can be used by the PCP to help
determine if urgent referral to crisis specialty care is needed (ICSI, 2016; Siu et al., 2016).
Adequate screening, assessment, diagnosis, and treatment is needed to reduce the
incidence, prevalence, and recurrence of depression as well as the chronicity of the disease, and
PCPs are instrumental in reducing the burden of depression and improving the quality of care.
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With fewer than half of all individuals who experience depression seeking treatment, PCPs
should promote awareness, adequately screen, and help to reduce the stigma surrounding mental
health, in an effort to overcome barriers to access to care (ICSI, 2016; Mauer 2012; WHO;
2017). Despite the availability of various efficacious treatments for depression, the risk of
relapse remains extremely high with recurrences, severity, and treatment resistance everincreasing (Gilli, Vicens, Roca, Anderson, & McMillan (2015). Considering these issues, PCPs
should work at developing interventions geared toward preventing relapse or recurrence of
depression and for overall prevention, as these are major concerns regarding the long-term
management and care of patients with depression (Gilli et al., 2015). Routine screening for
depression and adherence to the ICSI (2016) health care guidelines for adult depression in
primary care can help guide PCPs in achieving improved recognition, diagnosis, and treatment
of MDD in the primary care setting.
Assessment
An independent family medicine practice located in an urban city of South-Central Texas
was the site for implementation of an evidence-based quality improvement project aimed at
aligning the clinic with the ICSI 2016 guidelines for adult depression in primary care for the
screening, diagnosis, treatment, and management of patients with MDD. The staff involved in
the project at the clinic included the providers (one physician, three physician assistants), four
receptionists, three medical assistants, one licensed vocational nurse, one referral coordinator,
and an office manager.
The clinic sees an average of 600 patients per week. Roughly 1% of patients are 12 to 17
years of age, 17% are 18 to 24 years of age, 26% are 25 to 44 years of age, 34% are 45 to 64
years of age, and 22% are 65 years of age and over. Patients’ ethnic/racial backgrounds are
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60.4% Hispanic, 56.2% White Non-Hispanic, 1.4% Black, 1.3% Asian, and 0.7% classified as
“other.” The male to female ratio is estimated at 50:50. A majority of the patients speak Spanish
or English, with the greatest preference typically being Spanish. All of the clinic’s staff are
bilingual and speak both English and Spanish, with the exception of one staff member.
Demographics of the patients served at the clinic are comparable to those of the county in which
it is located (Health Collaborative 2016; U.S. Census Bureau, 2016). Approximately 27% of
patients seen within the clinic over 6 months (June 2018-December 2018) sought psychiatric
services or care, with 21% of those patients having a diagnosis of MDD.
A community health needs assessment for the county in which the clinic is located
identified depression as being one of the community’s top priorities and the most common
mental health issue requiring complex solutions and interventions (Health Collaborative, 2016).
This predominately Hispanic community has low income and poverty rates that are higher than
average in comparison to national rates, as well as low educational levels and health literacy,
which contributes to the community’s increased risk for depression (Health Collaborative, 2016).
Key barriers to care identified for those with mental illness within this community were a lack of
involvement and awareness of behavioral health issues by PCPs, a low number of referrals to
behavioral health specialists by PCPs, a heavy reliance on medications by PCPs for mental
health issues when other interventions may be necessary or potentially more effective, and a lack
of collaboration with or connection by PCPs to behavioral health resources within the
community (Health Collaborative, 2016). According to the National Alliance on Mental Illness,
Hispanics are less likely to utilize behavioral health specialty services, further highlighting the
need for improvements in care at this clinic for patients with depression (Health Collaborative,
2016). With the clinic’s patient population and surrounding community being predominately
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Hispanic, having multiple health disparities, and at an increased risk for depression, there is a
critical need to enhance the management of depression at this clinic.
An October 2018 microsystem assessment was performed, and indicated that the clinic
and the providers lacked the uniform use of evidence-based guidelines for the screening,
diagnosis, treatment, and management of MDD. Various guidelines were being utilized by the
providers when providing care for depressed patients, with diagnosis being based primarily on
the DSM-IV diagnostic criteria for depression. Screening of patients for depression was not
being conducted in the clinic and clear evidence-based protocols were lacking regarding the
treatment, referral, and follow-up for patients with MDD. A protocol was also lacking for the
management of patients with depression expressing suicidal ideation and/or those posing an
imminent threat to the safety of themselves or others. The providers lacked a uniform approach
regarding this issue and indicated that the patient was typically advised to seek care at a local
emergency department and if the patient refused, a relative of the patient was notified to help
convince the patient to seek emergency care. However, if the patient refused to seek emergent
care as advised, it was uniformly expressed by the providers that they could not intervene any
further unless the patient was actively harming themselves or someone else in the clinic. This
established a need for provider education and a protocol to address this safety concern.
The clinic’s referral resources for mental health specialists were very limited and
outdated. The ICSI guidelines call for the universal and routine screening for depression in adult
patients, use of the DSM-5 for the diagnosis of MDD, and an adequate system of care in place
and aligned with evidence-based guidelines to ensure accurate diagnosis, effective treatment, and
appropriate follow-up for the management of MDD. The clinic lacked uniform use of evidencebased guidelines for the screening, diagnosis, treatment, and management of patients with MDD.
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Readiness for Change
Results of the October 2018 microsystem assessment and the ICSI guidelines were
discussed and reviewed with key stakeholders and it was established that the clinic was not
aligned with the ICSI’s 2016 guidelines for adult depression in primary care. Prior to being
apprised of the ICSI guidelines, the providers had been unaware of the recommendation for
universal and routine screening of adult patients for depression and the clinical utility of PHQ-9
for the screening, monitoring of severity and treatment outcomes, and management of
depression. Successive review of the guidelines indicated that a protocol needed to be developed
to align the clinic with the ICSI guidelines. The providers in the clinic were motivated to
improve the quality of care for depression in the clinic and were very receptive to the project. All
staff and providers in the clinic expressed enthusiasm and a desire to participate in the project
and the implementation of the evidence-based ICSI guidelines for adult depression in primary
care in the clinic as a way to improve the quality of care.
Project Identification
Purpose and Objectives
The purpose of this evidence-based quality improvement project was to improve
adherence of the clinic’s PCPs to the ICSI's 2016 health care guideline for adult depression in
primary care, and consequently improve the quality of care provided for adult patients with
major depressive disorder. The ICSI guidelines call for routine screening for depression in adults
aged 18 and older, with adequate systems of care in place, and can be used by PCPs to support
the effective diagnosis, treatment, and management of major depression in the primary care
setting.
The objectives of this evidence-based quality-improvement project were to:
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1. Increase screening for depression for adult patients from the pre-intervention rate of
0% to 90% in 8 weeks, using Patient Health Questionnaire-2 (PHQ-2) and PHQ-9.
2. Increase the percentage of adult patients with an established diagnosis of depression
who are routinely assessed for severity of symptoms from the pre-intervention rate of
0% to 50% in 8 weeks, using PHQ-9.
3. Increase provider adherence rate to the MDD Suicide Protocol from the preintervention rate of 0% to 100% in in 8 weeks for patients who scored positive to
question 9 of PHQ-9.
4. Increase the percentage of referrals for adult patients with depression to mental health
specialists as appropriate, per the ICSI 2016 guidelines for adult depression in
primary care, from the pre-intervention rate of 0% to 50% by the completion of the
eighth week of project implementation.
Anticipated Outcomes
By meeting these objectives, there will be an increase in the recognition of depression in
adult patients, in the assessment of the presence and severity of depressive symptoms, in
provider adherence to the MDD suicide protocol, and in referrals for adult patients with major
depression to behavioral health specialists as appropriate, per evidence-based guidelines. The
clinic will align with the USPSTF’s recommendation for universal routine screening for
depression in adults and will be in compliance with the ICSI’s 2016 guidelines for adult
depression in primary care.
Summary and Strength of Evidence
Depression is a widespread, debilitating, and treatable psychiatric illness most commonly
managed and treated within the primary care setting (ICSI, 2016). A majority of patients in the
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United States with depression are being seen and treated in the primary care setting and, despite
effective treatment being available, outcomes remain suboptimal in primary care. Extensive
literature supports the assertion that depression is underdetected, underdiagnosed, and
undertreated by PCPs (ICSI, 2016; Siu, 2016; WHO, 2018). Screening is key in the prevention of
depression, as effective recognition, diagnosis, and treatment is linked with lower chronicity,
morbidity and mortality, recurrence, and incidence (CDC, 2017; Maurer, 2012; Maurer et al.,
2018; Scrandis & Watt, 2013). The USPSTF found substantial evidence that screening improves
the accurate identification of depression in adult patients in primary care settings, yet screening
rates for depression continue to remain astoundingly low in primary care (ICSI, 2016; Siu et al.,
2016).
The ICSI guidelines and the USPSTF recommend routine universal screening for
depression in all adults, 18 years of age and over, at least annually when accompanied by
systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up
(ICSI, 2016; Maurer et al., 2018; Scrandis & Watt, 2013). Although screening for depression in
adults in primary care is supported within the literature as being beneficial with adequate systems
of care in place, evidence fails to distinguish the optimal timing and intervals for screening or
what actually comprises adequate systems of care (ICSI, 2016; Siu et al., 2016).
Screening for depression is commonly done with validated tools such as PHQ-2 and
PHQ-9, which are cornerstones in supporting the diagnosis of depression and for monitoring
progress with treatment (ICSI, 2016; Maurer et al., 2018; Siu et al., 2016). The PHQ-2
assessment is a brief, valid, and reliable two-question screening tool that can be used for initial
intake and routine screening for depression (ICSI, 2016; et al., 2016; Siu et al., 2016). One of
the most efficacious screening tools used in primary care is PHQ-9, which has been validated to
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detect depression and monitor the presence and severity of depressive symptoms (ICSI, 2016;
Scrandis & Watt, 2013). If a patient screens with a positive PHQ-2 result, PHQ-9 screening tool
can be administered and is supported in the literature as being an effective tool in the primary
care setting to confirm the diagnosis, assess the severity of symptoms and suicidality, and
monitor response to treatment for depression (ICSI, 2013; Maurer et al, 2018; Mitchell,
Yadegarfar, Gil, & Stubbs, 2016; Siu et al., 2016). The PHQ-9 assessment is identified
extensively throughout the literature as being an effective management tool for depression and
can be used routinely for follow-up visits to monitor the severity and treatment of outcomes
(ICSI, 2016; Mitchell et al., 2016; Siu et al., 2016). The clinical utility of PHQ-9 for the
management of depression in primary care is extensively supported in the literature, as it can be
used by PCPs to help guide and modify treatment plans (ICSI, 2013; Maurer et al., 2018;
Mitchell et al., 2016; Siu et al., 2016). PHQ-9 results and side effect evaluation, combined with
evidence-based treatment algorithms, can help PCPs to push patients with depression toward
remission (ICSI, 2013; Maurer et al., 2018; Mitchell et al., 2016; Siu et al., 2016).
A multitude of studies suggest that screening for depression in clinical practice without
adequate systems of care in place is of minimal benefit (Cameron et al, 2014; ICSI, 2016;
Maurer, 2012; Mitchell et al., 2016; Siu et al., 2016). Programs implementing depression
screening in conjunction with adequate support systems are emphasized as being crucial and
beneficial (Cameron et al, 2014; ICSI, 2016; Maurer, 2012; Mitchell et al., 2016; Siu et al.,
2016). Adequate systems of care are commonly identified in the literature as having sufficient
clinical staff to ensure that patients are screened and, if the patient screens positive, that
evidence-based care is being provided to ensure appropriate diagnosis, treatment, referral, and
follow-up (Cameron et al, 2014; ICSI, 2016; Maurer, 2012; Mitchell et al., 2016; Siu et al.,
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2016). The lowest level of support necessary to implement effective screening for depression
was supported in the literature as requiring, at a minimum, a staff member to advise PCPs of
positive screening results, and a protocol that facilitates referral to evidence-based treatment for
depression (Cameron et al, 2014; ICSI, 2016; Maurer, 2012; Mitchell et al., 2016; Siu et al.,
2016). A meta-analysis of 52 randomized controlled trials compared the effects of treatment with
antidepressants alone versus combined treatment with antidepressants and psychotherapy for
adult patients with depression, and results indicated that monotherapy with antidepressants may
not constitute optimal treatment for depression and that combined treatment to include
antidepressants and psychotherapy is more effective than antidepressant medication alone for the
treatment of depression (Cuijpers et al., 2014). A multidisciplinary team-based approach that
encompasses self-management support and care coordination is widely supported in the literature
as being effective for the management of depression in primary care (Cameron et al, 2014; ICSI,
2016; Maurer, 2012; Siu et al., 2016). Recent studies have found that approximately 25 to 60%
of individuals contemplating suicide seek attention for a medical problem from a PCP in the
weeks prior to death and typically do not seek psychiatric help, which highlights the need for
adequate systems to be in place in primary care settings to help identify and monitor patients at
risk for suicide (SAMHSA-HRSA, 2019). A multitude of literature supports the recommendation
of screening patients for suicidal ideation using a standardized screening tool such as PHQ-9
(Ingelse, 2016). The PHQ-9 assessment can be used to identify individuals at risk for suicide and
has been found to be more reliable than clinical judgement or assessment alone (ICSI, 2016;
Ingelse, 2016; SPRC, 2017). Further research is needed to identify, assess, and address barriers
in establishing adequate systems of care (ICSI, 2016; Mitchell et al., 2016; Siu et al., 2016).
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Methods
Project Intervention
Prior to project implementation, screening for depression or suicide ideation with a
validated instrument was not being conducted by PCPs within the clinic. Referrals to a
behavioral health specialist for patients with a diagnosis of MDD were very infrequent and were
not based on evidence-based guidelines for depression. Overall, the clinic lacked uniform use of
evidence-based guidelines by PCPs for screening, diagnosis, treatment, and management of
patients with MDD. Routine screening for adults 18 years of age or older for depression in the
primary care setting using PHQ-2 and PHQ-9 has been shown to improve detection, diagnosis,
and outcomes of depression (ICSI, 2016). PHQ-2 is a valid assessment instrument for detecting
depression and has been established to be up to 97% sensitive and 67% specific in adults
(Maurer, 2012). The PHQ-2 assessment scores range from 0 to 6, with a cut point of ≥ 3, which
suggests clinically significant that should prompt further screening and assessment with PHQ-9
(ICSI, 2016). PHQ-9 is a valid assessment tool for measuring depression severity, and for
detecting and monitoring depression in the primary care setting, with a sensitivity of 0.77 and a
specificity of 0.85 in adults (ICSI, 2016). PHQ-9 can be used by PCPs to help identify
depression and to guide and monitor treatment. However, these screening tools should only be
used by PCPs to enhance and not replace the clinical interview (ICSI, 2016). Screening of the
general adult population with the combination PHQ-2 and PHQ-9 can improve the detection,
diagnosis, outcomes, and functioning for patients with depression (ICSI, 2016).
Prior to project implementation, one-on-one interactive education was carried out with
each PCP on the screening, diagnosing, treatment, referral, and management of MDD and
included the screening procedure using PHQ-2 and PHQ-9, how to score and interpret PHQ-2
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and PHQ-9, DSM-5 criteria for diagnosing MDD, how to translate PHQ-9 depression scores into
practice based on DSM-5 criteria and ICSI guidelines, PHQ-2 and PHQ-9 screening timing and
interval, how to assess and minimize suicide or homicide risk, when to refer to a behavioral
health specialist, and how to use PHQ-9 scores to monitor treatment response and severity of
MDD (see Appendix M). Each PCP in the clinic was provided with a copy of the clinic’s MDD
Provider Handbook, which included a copy of the ICSI 2016 guidelines, copies of the PHQ-2
assessment and PHQ-9 assessment with instructions on how to score and interpret the forms, a
copy of DSM-5 criteria for MDD (see Appendix J), a copy of MDD in primary care (see
Appendix K), a copy of the clinic’s MDD provider algorithm (See Appendix L), a copy of MDD
provider treatment recommendation table (see Appendix M), and a copy of the clinic’s MDD
suicide protocol for the assessment, management, and, minimization of suicide risk (see
Appendix N). The project implementation plan was discussed through one-on-one interactive
education sessions provided to all clinic staff regarding their roles and responsibilities during the
implementation phase of the project. Laminated copies of the MDD provider algorithm and the
MDD provider treatment recommendation table were posted in each patient room within the
clinic for provider referral. Laminated copies of the first two pages of the MDD suicide protocol
were posted for reference on the wall in the provider area, near the referral coordinator’s desk,
near the office manager’s desk, and on the counter in the front reception area. Data collection
sheets were color coordinated according to provider in order to track weekly provider adherence
screening rates.
Also prior to project implementation, a referral system was initiated and established with
a nearby psychiatric outpatient clinic. Collaboration between the psychiatrist/owner of the
psychiatric practice and the medical director/owner of the clinic was fostered in an effort to
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increase referrals to mental health specialists, as suggested in ICSI guidelines. An online referral
portal was established by the nearby psychiatric outpatient clinic in the EHR at the project
site/clinic in which same-day/immediate or routine referrals could easily be made online by the
PCPs, as needed.
Beginning on day one of implementation, all adult patients aged 18 years and older being
seen in the clinic were administered PHQ-2 form in English or Spanish, based on their language
preference, by the front desk receptionist to screen for depression. Verbal consent from the
patient to administer PHQ-2 was obtained by a front desk staff member, who filled in the
applicable section of the data collection forms, which were color coded and selected based on the
provider seeing the patient. Once the PHQ-2 form was completed, the patient returned the form
to the front desk receptionist, who then placed it with the patient's face sheet and appropriate data
collection sheet in a bin for the Licensed Vocational Nurse (LVN) or Medical Assistant (MA)
responsible for triaging and rooming the patient. The LVN or MA took the completed PHQ-2
form, data collection form, and the patient’s face sheet with them as they roomed the patient and
obtained vital signs. The LVN or MA scored the PHQ-2 form and made note on the patient’s
face sheet and data collection form of the PHQ-2 score and result. The LVN or MA then
determined whether or not the patient had a previous or existing diagnosis of depression by
reviewing the face sheet with previous diagnoses listed and by asking the patient. If the patient
had a current or previous diagnosis of depression, or if they screened positive for depression
using PHQ-2 with a score of at least three or greater, the LVN or MA administered PHQ-9 to the
patient in their room to complete while they were waiting to be seen by their PCP.
The PCP interpreted the PHQ-2 results and then scored and interpreted the results of the
PHQ-9 test. The PCP used the PHQ-9 assessment to help determine the severity of depressive
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symptoms and to establish a baseline for patients without a previous diagnosis of depression or
for the monitoring of treatment response and severity of depressive symptoms for patients with a
previous diagnosis of MDD. The PCP assessed all patients with a positive PHQ-2 result for
suicidal ideation using Question 9 of the PHQ-9 and in accordance with the clinic’s MDD
suicide protocol. The PCP followed the MDD provider algorithm, the provider treatment
recommendation table, and the clinic’s MDD suicide protocol for the assessment and
minimization of suicide risk and for the treatment of the patient. The PCP recorded the PHQ-9
score, whether or not the patient had a positive response for Question 9 of PHQ-9, whether or not
the patient was assessed for SI, whether or not the patient was positive for SI, and whether or not
the patient was referred to a mental health specialist, to include the reason the referral was made
or not made on the data collection form.
Referral of the patient to a behavioral health specialist, for inpatient evaluation or
treatment, or for further psychiatric treatment was made by the PCP and based on their clinical
judgment and the clinic’s MDD provider algorithm, MDD provider treatment recommendation
table, and the MDD suicide protocol. After seeing the patient, the PCP was responsible for filing
the data collection sheets in a file folder according to the day of the week.
The implementation phase was conducted over an eight-week period in which every adult
patient aged 18 and older was initially screened for depression using PHQ-2. Patients with a
previous diagnosis of depression or who screened positive for depression using PHQ-2 (score ≥
3) were also administered PHQ-9 and screened further for depression to help establish a
diagnosis and/or baseline of MDD, assess the severity of depressive symptoms, and assess for
the presence of suicidal ideation. All patients with a previous diagnosis of MDD during the
eight-week implementation phase were administered PHQ-9 routinely at every visit to monitor
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treatment response and the severity of depressive symptoms. All patients being seen by a
provider in the clinic during the first eight weeks of project implementation were included in
post-intervention data collection and analysis.
Data Collection sheets were kept in a file folder and stored in a locked drawer in the
clinic’s provider area. The data collection sheets were reviewed weekly in the clinic and data was
entered and tracked using an excel spreadsheet. Weekly screening rates were calculated for the
providers by comparing the daily ledger of their patients to their total number of data collection
forms for each day. Results for provider adherence were posted weekly in the clinic’s breakroom
to encourage provider adherence and project participation.
Organizational Barriers and Facilitators
Organizational barriers identified included resistance to change by staff; time constraints
for PCPs and front desk receptionists related to the implementation of screening, which is a fastpaced and time sensitive environment; and high staff turnover. PCP resistance to referring
patients with depression to behavioral health specialists was another barrier to the project, and to
increasing referral rates to behavioral health specialists, as this was viewed by a majority of the
PCPs as losing revenue. Unforeseen circumstances occurred in which only three providers were
able to participate for a duration of 6 weeks during project implementation, with only two
providers participating the entire 8-week duration of project implementation. Lastly, high
turnover of front desk staff occurred during project implementation, which required
modifications to be made to the screening process with PHQ-2. Consequently, the LVN or MA,
instead of the front desk reception staff, were responsible for administering both the PHQ-2 and
PHQ-9 screening tools while rooming and triaging the patients for the remaining phase of project
implementation.
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Potential project facilitators included the clinic staff’s willingness to change and improve
processes for the diagnosis, treatment, and management of MDD, and increased visits and
reimbursements for the clinic related to screening with PHQ-2 and PHQ-9. The providers were
very open to collaborating with behavioral health specialists to improve care for adult
depression. Collaborations between the owner of the primary care clinic in which the project was
implemented and with a psychiatrist and owner of a nearby psychiatric outpatient facility was
fostered and established, which resulted in a system for referral and collaborative care. An
electronic referral portal was implemented by the office manager of the psychiatric facility into
the EHR at the clinic, in which providers could schedule same-day or routine psychiatric
appointments for patients in need of referral. The providers were very satisfied with the user
friendliness of the referral portal and uniformly expressed that having a psychiatric referral
source with immediate availability would increase the referral rate to behavioral health
specialists, because a perceived barrier to patients being referred was the long wait times to be
seen by a behavioral health specialist.
Ethical Considerations
Screening for depression can lead to false positive results and consequent inappropriate
diagnosis and treatment (Sheehan & McGee, 2013). Literature suggests that screening alone
cannot be used to establish the diagnosis of depression and is only beneficial with adequate
systems of care in place to ensure accurate diagnosis, treatment, and follow-up (Siu et al., 2016).
Screening positive for depression also involves implications for confidentiality and informed
consent (Sheehan & McGee, 2013). Confidentiality should be maintained at all times and
consent should be obtained from the patient prior to screening for depression regarding the
disclosure of information and how it will be used (Sheehan & McGee, 2013). At the clinic,

IMPROVING PROVIDER ADHERENCE TO MDD GUIDELINES

30

patient confidentiality of positive screening results was maintained at all times and patients were
made aware of how the screening results would be handled. Verbal consent from the patient was
obtained by clinical staff prior to administration of PHQ-2 and/or PHQ-9.
Screening for suicide risk in patients can pose ethical concerns for providers, as the ICSI
guidelines recommend emergency detention for patients who refuse treatment and are deemed to
be imminently dangerous to themselves or others (ICSI, 2016). Seeking emergency detention for
a patient requires the provider to report the threat to local law enforcement and breach patient
confidentiality (ICSI, 2016). Consequently, the provider may be confronted with an ethical and
legal dilemma in which the duty to maintain the patient’s confidentiality conflicts with the duty
to protect the patient’s and public’s health and safety. Currently, there is no national consensus
on whether a provider has a duty to warn individuals who are not his or her patients who could
foreseeably be endangered, to protect them, or both (McMullen, Howie, & Philipsen, 2013).
Although national consensus doesn’t exist regarding the duty to warn, the seminal case (Tarasoff
v. Regents of the University of California, 1976) set a standard of duty to protect third parties
against harm and, although only legally binding in California, has had far reaching implications
and has set legal standards in many states across the nation (Barloon & Hilliard, 2016). In
accordance with Texas Health and Safety Code §611.004 (2005), Texas is a permissive state and
the healthcare provider has no duty to inform law enforcement of a threat of violence and is
granted a permissive duty to warn, with the decision of whether to warn or not to warn being left
up to the provider (McMullen et al., 2013). Providers should consider the legal, ethical, and
moral aspects and be familiar with pertinent rules, laws, and regulations to help address the
dilemma and to avoid any possible legal action (McMullen et al., 2013).
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Results
In order to evaluate outcomes for the project, the percent change from pre-intervention to postintervention was calculated for each objective after 8 weeks of intervention implementation (see
Figure 1). The percentage increase calculation can be used to measure the success of the project
objectives and to determine if goals were met, as the pre-intervention number for each objective
was zero. The percentage increase calculation can be determined by working out the difference
between the two numbers (number of patients’ post-intervention minus number of patient’s preintervention), which determines the percentage increase. The percentage increase calculation can
then be used to determine if screening for depression with PHQ-2 and PHQ-9 for adult patients
increased, if the percentage of adult patients with depression who were assessed by PCPs for the
presence and severity of depressive symptoms increased with use of PHQ-9, if the percentage of
providers adhering to the MDD suicide protocol increased, and if the percentage of referrals for
adults with depression to a behavioral health specialist increased using the ICSI guidelines for
(see Table 1).

Objective 1: PHQ-2 Screening Rate

90%
97%

Objective 1: PHQ-9 Screening Rate

90%
94%

Objective 2: PHQ-9 Routine Assessment
Rate
Objective 3: Provider Adherence Rate to
Suicide Protocol
Objective 4: Referral Rate to Behavioral
Health Specialist
Goal

50%

81%
100%
100%

26%

50%

Outcome

Figure 1. Objective outcomes: Percent change from pre-intervention to post-intervention for
each objective.
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Objective 1
The first objective aimed to increase the screening rates for adult depression by 90%
using PHQ-2 and PHQ-9. During the 8-week project implementation period a total of 2,312 adult
patients were seen in the clinic and were eligible for initial screening for depression with PHQ-2,
with 2,242 (97%) of those patients actually being screened (see Figure 2). Of the 2,242 patients,
670 (30%) screened using PHQ-2 scored positive (PHQ-2 score  3), with 71 out of the 670
(11%) patients scoring positive already having an existing diagnosis of depression, and 599 out
of the 670 (89%) patients scoring positive without a previous diagnosis of depression. Of the
2,242 patients, 86 (4%) screened using PHQ-2 scored negative with an existing diagnosis of
Table 1
Demographic Characteristics of Patients
Characteristics

n = 2,312

%

Male

1,087

47%

Female

1,225

53%

White (Non-Hispanic)

1,018

44%

Hispanic

1,225

53%

African American

23

1%

Other

46

2%

486

21%

25–44

786

34%

45–64

647

28%

Gender

Race/Ethnicity

Age (in years)
18–24
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depression and were also eligible for further screening with PHQ-9. The total number eligible for
further screening with PHQ-9 were 756 patients. A total of 711 of the 756 eligible patients (94%)
were actually screened using PHQ-9 (see Figure 3). Of the 711 adult patient, 585 (82%) without
a previous diagnosis of depression were screened for depression to establish a baseline using
PHQ-9, while 126 (18%) of adult patients with a previous or existing diagnosis of depression
were screened further for depression using PHQ-9 to monitor the severity of depressive
symptoms and treatment response (see Figure 5). Of the 585 patients who scored positive on
PHQ-2 without an existing diagnosis of depression and who were screened further with PHQ-9,
205 (35%) scored positive for depression (PHQ-9 score  10) and were newly diagnosed (see
Figure 4). Total screening rates for all adult patients during project implementation using PHQ-2
was 97% (see Figure 2), while the total screening rate using PHQ-9 was 94% (see Figure 3). The
screening rates for depression in adults increased from the pre-intervention rate of 0% to post
intervention by 97% using PHQ-2 and by 94% using PHQ-9 (see Figure 1).

3%

97%

Screened

Missed Opportunity to Screen

Figure 2. Eligible patients screened for depression by PCP using PHQ-2 (n = 2,312).
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6%

94%

Screened

Missed Opportunity to Screen

Figure 3. Eligible patients screened for depression by PCP using PHQ-9 (n = 756).

35%

65%

Screened Positive

Screened Negative

Figure 4. PHQ-9 Screening results for patients without a previous diagnosis of
depression (n = 585).
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28%

72%

Screened Positive

Screened Negative

Figure 5. PHQ-9 screening results for patients with a previous diagnosis of depression (n =
126).

Objective 2
The second objective aimed to increase the percentage of patients with depression who
were routinely screened for the severity of symptoms using PHQ-9 by 50% post intervention. A
total of 157 adult patients with an existing diagnosis of depression were initially screened in the
clinic during project implementation using PHQ-2 and were eligible for further screening using
PHQ-9. Of the 157 patients eligible to be screened with PHQ-9, 126 patients (81%) were
actually screened to assess the severity of depressive symptoms (see Figure 6). Overall,
screening and assessment in patients with depression by PCPs for the severity of depressive
symptoms using PHQ-9 increased from a pre-intervention rate of 0% to a post-intervention rate
of 81% (see Figure 1).

IMPROVING PROVIDER ADHERENCE TO MDD GUIDELINES

36

19%

81%

Screened

Not Screened

Figure 6. Patients with a previous diagnosis of depression that were screened and assessed by
the PCP using PHQ-9 (n = 126).

Objective 3
The third objective aimed to increase provider adherence to the MDD suicide protocol by
100% for patients responding positively to question 9 of PHQ-9. A total of 711 patients were
assessed by the PCP for suicidality using Question 9 of PHQ-9. Of the 711 patients, 14 (0.02%)
who were screened with PHQ-9 had a positive response to question 9 (see Figure 7). The
providers adhered 100% to the MDD suicide protocol for the 14 patients scoring positive to
question 9 of PHQ-9, with all 14 patients being further assessed for suicide, referred, and
followed up appropriately, per the MDD suicide protocol. Of the 14 patients responding positive
to Question 9 of PHQ-9, only 3 of those patients (21%) were actually deemed to be of high
suicide risk and were appropriately and immediately referred to a behavioral health specialist
(see Figure 8).
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0.02%

99.08%

Positive Response

Negative Response

Figure 7. Patient responses to Question 9 of PHQ-9 (n = 711).

27%

73%

Routine

Immediate

Figure 8. Referral types made by the PCP to a behavioral health specialist for
patients responding positively to Question 9 of PHQ-9 (n = 14).
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Objective 4
The fourth objective aimed to increase the referral rate for patients with depression to a
behavioral health specialist per ICSI guidelines by 50%. A total of 75 out of 288 patients (26%)
eligible for referral to a behavioral health specialist who either had depression (PHQ-9 score 
10) or were deemed a high suicide risk were referred to a behavioral health specialist. Of the 75
referrals made, 72 (96%) were for routine referral to a behavioral health specialist, while the
remaining 3 (4%) were made for immediate referral due to high suicide risk (see Figure 9). Of
the 288 patients, 213 (74%) with depression (PHQ-9 score  10) who were eligible for referral to
a behavioral health specialist were not referred (see Figure 9). The reasons for non-referral to a
behavioral health specialist were documented by the providers on the data collection form and
were categorized as either not being indicated, not being needed as treatment was being provided
by the PCP, or due to an other unspecified reason, with 41 patients (19%) being documented by
the providers as “not indicated,” 134 patients (63%) being documented as not being made due to
“treatment being provided by the PCP,” and the remaining 38 patients (18%) being documented
as not being referred due to “other” reason (see Figure 10). Although the objective goal was not
specifically met, the referral rate for patients with depression to a behavioral health specialist
using the protocols and ICSI guidelines increased by 26% post-intervention, falling short of the
goal of 50% (see Figure 1).
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25%
1.00%
75%

Routine Referral

Immediate Referral

No Referral Made

Figure 9. Referral types made by PCP for eligible patients to a behavioral health specialist (n =
288).

Discussion
Although this quality improvement project successfully increased the screening rates for
depression using PHQ-2 and PHQ-9, the overarching aim was to improve provider adherence to
ICSI guidelines for the treatment and management of adult depression, to improve the quality of
care and patient outcomes. The MDD protocols developed for this project were useful at
initiating change toward improving provider adherence to evidence-based guidelines for adult
depression. However, additional time and further exploration would be needed beyond the scope
of this project to fully determine if the quality, efficiency, and effectiveness of care were
improved for adults with depression and to identify and adequately address any specific areas of
weakness.

IMPROVING PROVIDER ADHERENCE TO MDD GUIDELINES

18%

40

19%

63%

Not Indicated

Treatment Provided by PCP

Other

Figure 10. Reasons per PCP for non-referral of eligible patients to a behavioral health specialist
(n = 213).

The project successfully increased screening rates and the recognition and diagnosis of
depression for patients being seen in the clinic who may have otherwise gone undetected.
However, research extensively supports that screening alone does not translate into significant
improvements in care and patient outcomes (Picardi et al., 2016). Previous studies targeting
depression screening in primary care settings have demonstrated the significance of having
adequate resources and systems of care in place to allow for further evaluation, treatment, and
follow-up, if needed, as screening without support is futile and can create a potential for liability
(ICSI, 2016; Siu et al., 2016). Evidence also supports a need for collaborative care between PCPs
and behavioral health specialists, in combination with screening, as being crucial to improving
treatment adequacy, patient outcomes, and the quality of care for adult patients with depression
in primary care settings (Cuijpers et al., 2014; ICSI, 2016). Collaborative care and additional
psychotherapy have been supported extensively in the literature as being more beneficial to
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patients with depression in comparison with pharmacotherapy alone, with psychotherapy being
the most strongly linked to long-term prevention of relapse (Ostergaard & Moldrup, 2011).
Overall, the interventions were successful in improving provider adherence to ICSI
evidence-based guidelines for the screening, treatment, and management of depression in adults.
Screening rates for depression using PHQ-2 and PHQ-9, the routine assessment of the severity of
depressive symptoms in depressed patients using PHQ-9, provider adherence rate to the MDD
suicide protocol, and the referral rate for adults with depression to a behavioral health specialist
increased from pre-intervention to post-intervention. The MDD provider handbook and protocols
developed for the clinic were useful in identifying, treating, and managing care for adult patients
with depression and for minimizing and managing the risks of suicide. The MDD provider
handbook was a valuable means to keep the providers informed of how to properly screen,
diagnose, treat, and manage care for adult patients with depression and for those at risk for
suicide, and provided adequate tools and resources for protocol completion. The MDD protocol,
which includes the MDD provider treatment algorithm, the MDD provider treatment
recommendation table, and the MDD suicide protocol is transferrable to other primary care
clinics and can be modified as needed to fit the individual needs of the clinic and staff.
Limitations
A major limitation to the project was the time constraint, as the project implantation
phase could only be conducted for a period of 8 weeks, making it challenging to determine the
impact the interventions had on improving the quality of care for adults with depression (ICSI,
2016). The PHQ-9 assessment, in addition to being a valid standardized tool to screen for
depression, can also be used as measurement-based tool by the provider to quantify baseline
severity of depressive symptoms and to monitor treatment response. The measurement-based
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approach using PHQ-9 can help the provider determine the efficacy of treatment by comparing
the baseline PHQ-9 score to the PHQ-9 score/s performed during subsequent visits (Anderson,
2011; APA, 2010; Maurer, 2012). A 50% reduction in depressive symptoms, or of the PHQ-9
score, should be achieved within 8 weeks from the initiation of treatment, with a PHQ-9 score of
less than 5 indicating remission of the depressive episode (APA, 2010; Anderson, 2011;
Cameron et al., 2014; ICSI, 2016). PHQ-9 scores can be used by the provider as a measurementbased approach to ascertain treatment response, remission rates, and recurrence rates and can
help guide the patient to remission (ICSI, 2016; Siu et al., 2016). However, project
implementation was limited to 8 weeks and more time would be needed to fully measure
treatment response, remission rates, and recurrence rates to determine the effectiveness of the
routine use of the PHQ-9 in improving patient outcomes.
Although screening with PHQ-2 and PHQ-9 for depression improved the recognition of
depression and suicide risk in patients, positive screening results for depression and suicide risk
resulted in increased time and utilization of resources. Time constraints associated with
screening for depression was a barrier voiced by staff during project implementation, as
additional time was required by providers to discuss PHQ-2 and PHQ-9 screening results and
related treatment interventions. Despite this barrier, the clinic’s MDD protocol helped serve as a
guide for the clinical staff and efficiency of care seemed to improve as they became more
familiar with the protocol.
Referrals to behavioral health specialists per ICSI guidelines could not adequately be
measured by this project, as the measures used (PHQ-9 scores of  10; high suicide risk) did not
fully capture all ICSI’s guideline recommendations for referral to a behavioral health specialist.
In addition, the data collection form only captured two specific reasons for non-referral, which
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included “not indicated” and “treatment being provided by PCP,” and one non-specific reason of
“other.” The “other” option, which was to be completed by the provider on the data collection
form, was followed by a blank space, with the intention of having the provider specify the reason
by filling in the blank. However, providers did not write out the “other” reason and instead
circled the option, which did not provide insight into other possible reasons for non-referral.
Further exploration would be needed to determine areas of weakness and in-depth reasons for
non-referral in order to improve referral rates for depressed patients to behavioral health
specialists per ICSI guidelines.
Recommendations
With the project’s findings and limitations in mind, it should be recognized that screening
for adult depression in primary care is only beneficial in combination with adequate practices
being in place to enhance the diagnosis, treatment, and management of care. Screening for
depression alone does not translate to improved patient outcomes and quality of care (Picardi et
al., 2016). Collaborative care to include support from behavioral health specialists in
combination with screening has been associated with improved recognition of depression, patient
adherence to treatment, treatment adequacy, and patient outcomes in primary care settings (Jiao,
Rosen, Bellanger, Belkin, & Muennig, 2017). In order to enhance the results of this project, a
collaborative care approach should be utilized to monitor the severity of depression, to provide
adequate follow-up, and to ensure psychiatric referral for patients who are not improving or
responding to treatment (Jiao et al., 2017).
Time constraints related to screening for depression and positive screening results proved
to be a major barrier for the clinical staff. The two-step screening approach with PHQ-2 and
PHQ-9 was performed using paper screening tools, which had to eventually be scanned and
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downloaded into the EHR, creating increased utilization of resources and time. Having the
screening tools already built into the EHR and having the patients complete PHQ-2 and PHQ-9
for every visit electronically prior to or upon check in may overcome the time and resource
barriers and may help to sustain the improved screening rates. It may also be beneficial to have
the MDD protocol integrated into the EHR to save time, improve provider adherence to
evidence-based guidelines, and ensure adequate diagnosis, treatment, referral, and follow-up.
The MDD protocol should continue to be used as a guide to improve provider adherence
to evidence-based guidelines and to enhance care and outcomes for adults with depression. PCPs
should continue to employ the measurement-based approach using PHQ-9 as a management tool
for depression, and routinely for follow-up visits, to monitor the severity and treatment outcomes
and to help guide and modify treatment plans. Treatment response, remission, and recurrence
rates should be measured regularly to successfully evaluate the impact that the interventions have
on improving quality of care for adults with depression and to continually sustain and/or improve
outcomes. Further exploration should be conducted to determine the specific reasons for nonreferral of depressed patients by PCPs to behavioral health specialists to improve the referral
process and better align the clinic with ICSI guidelines.
Implications for Practice
Development and adherence to evidence-based protocols by PCPs for the screening,
diagnosis, treatment, and management of adult depression in primary care can help push patients
toward remission and improve patient outcomes and overall quality of care. Implementation of a
suicide protocol can be useful in improving the recognition, assessment, and minimization of
suicide risk in depressed patients in the primary care setting. Findings of this evidence-based
quality improvement project support screening for depression in adults in the primary care
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setting using PHQ-2 and PHQ-9 can improve the recognition of depression in patients, which
may have otherwise gone undetected and untreated. Overall, screening for depression in adults in
combination with having adequate systems of care in place to ensure proper diagnosis, treatment,
follow-up, and management of depression is a cornerstone in improving quality of care and
patient outcomes.
With depression being underdetected, underdiagnosed, and undertreated in primary care,
Advanced Practice Registered Nurses can be instrumental in the improvement of the recognition,
diagnosis, and treatment of MDD. The Advanced Practice Registered Nurse is in a key position
to provide oversight and to successfully implement the necessary changes to improve provider
adherence to evidence-based guidelines for the screening, diagnosis, treatment, and management
of adult depression in primary care. Implementation of a similar MDD protocol with evidencebased guidelines and adequate screening for depression has the potential to significantly impact
not only the patient, but also their loved ones and society as a whole.
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PHQ-2 in Spanish
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PHQ-9 in English
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PHQ-9 Scoring and Interpretation
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Appendix H
MDD Provider Handbook & Education Plan
MDD Provider Handbook Materials: Copy of the ICSI Guidelines for each PCP, copies of the
PHQ-2 and PHQ-9 in English and Spanish with instructions on how to score and interpret, copy
of DSM-5 diagnostic criteria for MDD, copy of clinic’s MDD Provider Treatment
Recommendation Table: Translating PHQ-9 Scores into Practice, copy of MDD in Primary Care,
copy of clinic’s MDD Suicide Protocol for the assessment, minimization, and management of
suicide risk, and copy of Data Collection Form
Education:
1) Screening Procedure using the PHQ-2 and PHQ-9
a. Instructions on how to fill out forms
b. Instructions on how to score forms
c. Instructions on how to interpret scores
2) DSM-5 Diagnostic Criteria for MDD
3) MDD in Primary Care: Common presentations, risk factors, how & when to screen for
depression using the PHQ-2 and PHQ-9, how to use the PHQ-9 to monitor treatment
response, and when to refer to behavioral health specialist
4) MDD Provider Treatment Recommendation Table: How to translate PHQ-9 depression
scores into practice based on DSM-5 criteria and ICSI guidelines
5) MDD Suicide Protocol to assess, minimize, and manage suicide risk
a. How to screen for suicide ideation using Question 9 of PHQ-9
b. How to assess suicide risk
c. Suicide risk factors
d. When to refer patient for inpatient psychiatric evaluation/treatment
e. Texas Legislation regarding emergency detention (Texas Health and Safety Code
611.004 & 574.034)
f. When, how, and who to contact for emergency detention
g. Local & national suicide prevention resources
6) Duties and responsibilities for completion of Data Collection Form
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Appendix I
DSM-5 Diagnostic Criteria for MDD

DSM-5 Diagnostic Criteria: Major Depressive Episode
To qualify for a diagnosis of major depressive episode, the patient must meet criteria A
through E:
A. Five or more of the following symptoms have been present and documented during the
same two-week period and represent a change from previous functioning; at least one of the
symptoms is either (1) depressed mood or (2) loss of interest or pleasure.
Note: Do not include symptoms that are clearly attributable to another medical condition.
1) Depressed mood most of the day, nearly every day, as indicated by either
subjective report (e.g., feels sad, empty, hopeless) or observation made by others
(e.g., appears tearful)
2) Markedly diminished interest or pleasure in all, or almost all, activities most of
the day, nearly every day (as indicated by either subjective account or
observation)
3) Significant weight loss when not dieting or weight gain (e.g., a change of more
than 5% of body weight in a month), or decrease or increase in appetite nearly
every day
4) Insomnia or hypersomnia nearly every day
5) Psychomotor agitation or retardation nearly every day (observable by others, not
merely subjective feelings of restlessness or being slowed down)
6) Fatigue or loss of energy nearly every day
7) Feelings of worthlessness or excessive or inappropriate guilt (which may be
delusional) nearly every day (not merely self-reproach or guilt about being sick)
8) Diminished ability to think or concentrate, or indecisiveness, nearly every day
(either by subjective account or as observed by others)
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9) Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation
without a specific plan, or a suicide attempt or a specific plan for committing
suicide
B. The symptoms do not meet criteria for a mixed episode.
C. The episode is not attributable to the physiological effects of a substance or to another
medical condition. Note: Criteria A-C represent a major depressive episode. Note: Responses
(Institute
Clinical
Systems
Improvement,
to a significant loss (e.g., bereavement, financial ruin,
lossesforfrom
a natural
disaster,
a serious 2016)
medical illness or disability) may include feelings of intense sadness, rumination about the
loss, insomnia, poor appetite and weight loss noted in Criterion A, which may resemble a
depressive episode. Although such symptoms may be understandable or considered
appropriate to the loss, the presence of a major depressive episode in addition to the normal
response to a significant loss should also be carefully considered. This decision inevitably
requires the exercise of clinical judgment based on the individual's history of and the cultural
norms for the expression of distress in the context of loss.
D. The occurrence of the major depressive episode is not better explained by schizoaffective
disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified
and unspecified schizophrenia spectrum and other psychotic disorders.
E. There has never been a manic episode or a hypomanic episode. Note: This exclusion does not
apply if all of the manic-like or hypomanic-like episodes are substance induced or are
attributable to the physiological effects of another medical condition. Severity is based on the
number of criterion, the severity of those symptoms and the degree of functional disability.


Mild, single episode ICD-10 F32.0, recurrent episode ICD-10 F33.0: Few, if any
symptoms in excess of those required to make the diagnosis are present, the
intensity of the symptoms is distressing but manageable, and the symptoms result
in minor impairment in social or occupational functioning.



Moderate, single episode ICD-10 F32.1, recurrent episode ICD-10 F33.1: The
number of symptoms, intensity of symptoms, and/or functional impairment are
between those specified for "mild" and "severe."



Severe, single episode ICD-10 F32.2, recurrent episode ICD-10 F33.2: The
number of symptoms is substantially in excess of that required to make the
diagnosis, the intensity of symptoms is seriously distressing and unmanageable,
and the symptoms markedly interfere with social and occupational functioning.
Further specifications include:
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In partial remission, single episode ICD-10 F32.4, recurrent episode ICD-10
F33.41: Symptoms of the immediately previously major depressive episode are
present, but full criteria are not met, or there is a period lasting less than two
months without any significant symptoms of a major depressive episode
following the end of such an episode.



In full remission, single episode, recurrent episode ICD-10 F33.42: During the
past two months, no significant signs or symptoms of the disturbance were
present.
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MDD in Primary Care
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MDD Provider Algorithm
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Appendix L
MDD Provider Treatment Recommendation Table: Translating PHQ-9 Scores into Practice
M D D P R O V I D E R T R E A T M E N T R E C O M M E N D A T I O N T A B L E : T R A N S L A T I N G P H Q -9
S C O R E S I N T O P R A C T IC E
*At every level of severity, add education, physical activity, and behavioral activation to standard

treatment r ecommendations.
P HQ -9
Score s

Sev er it y

Initial
Score: 5-9

Undef ined

P ossi ble D iag noses Treatm ent Reco mm e ndat ions
Stay in to uch:
Does not meet
a) I f no impro vement after o ne or more
criter ia for major
months, co nsider treat ing or referra l to
depressiv e d isorder
beha viora l hea lth.
Consider for
persi ste nt
b) If sympto ms deter iorate, start treat
depressiv e d isorder
make a refer ral.

Follow-up
Parti al re miss ion
Score: 5-9

ment or

Continue stepped therap ies approach.
Combin ed ps ychotherap y and
pharm acotherap y treat ment.

Per DSM -5:
Few, if a ny, s ympto ms in excess of those req uired to make the
diagnos is are prese nt, the inte nsity of the s ympto ms is d istress ing 10-14
but managea ble, a nd the s ympto ms res ult in min or impairment in
soci al or occ upat ional functioning.

Mild major
depressi on

Whe n unable to do co mbin ed therap y due to
pati ent prefere nces, a vailabili ty and
affordabil ity of the t reat ments, st art w ith
psychotherap y.
Init ially co nsider week ly contacts to e nsure
adequ ate e ngage ment, the n at least monthly.
Combin ed ps ychotherap y and
pharm acotherap y treat ment.

Per DSM -5:
The number of s ympto ms, inte nsity of s ympto ms, a nd/or
15-19
fun ctio n al im p airm en t are betw een tho s e s p ec ified fo r “m ild” an d
“s evere.”

Moderate m ajor
depressi on

Whe n unable to do co mbin ed therap y due to
pati ent prefere nces, a vailabili ty and
affordabil ity of the treat ments, start w ith
psychotherap y.
Init ially co nsider week ly contacts to e nsure
adequ ate e ngage ment, the n at least e very 2-4
weeks.
Combin ed ps ychotherap y and
pharm acotherap y treat ment.

Per DSM -5:
The number of s ympto ms is s ubsta ntially in excess of that
requi red to make the d iag nosis, the intensity of the s ympto ms is
seri ously distress ing a nd unma nagea ble, a nd the s ympto ms
marked ly interfere w ith soc ial and occ upat ional funct ioning.

≥ 20

Sev ere major
depressi on

Whe n unable to do co mbin ed therap y due to
pati ent prefere nces, a vailabili ty and
affordabil ity of the t reat ments, st art w ith
pharm acotherap y.
Week ly co ntacts until less se vere.
Consider start ing w ith med icat ion.

Meets DSM -5 cr iter ia for pers iste nt depress ive d isorder

Pure d ysth ymia

Meets DSM -5 cr iter ia for pers iste nt depress ive d isorder

Chro nic major
depressi on

Consider stepped care , wh ich includes
augmenting medicat ions a nd add ing
p s ycho therap y fo r p atien ts w ho do n ’t
impro ve.
Combin ed ps ychotherap y and
pharm acotherap y treat ment.

(Institute for Clinical Systems Improvement, 2016)
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MDD Suicide Protocol
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Data Collection Form
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